JP4401440B2 - ビンカアルカロイドの抗有糸分裂性ハロ誘導体 - Google Patents
ビンカアルカロイドの抗有糸分裂性ハロ誘導体 Download PDFInfo
- Publication number
- JP4401440B2 JP4401440B2 JP54247098A JP54247098A JP4401440B2 JP 4401440 B2 JP4401440 B2 JP 4401440B2 JP 54247098 A JP54247098 A JP 54247098A JP 54247098 A JP54247098 A JP 54247098A JP 4401440 B2 JP4401440 B2 JP 4401440B2
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- compound
- general formula
- deoxy
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940122803 Vinca alkaloid Drugs 0.000 title claims abstract description 7
- 230000002927 anti-mitotic effect Effects 0.000 title abstract 2
- 125000001475 halogen functional group Chemical group 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 239000003930 superacid Substances 0.000 claims abstract description 12
- 229910021630 Antimony pentafluoride Inorganic materials 0.000 claims abstract description 6
- VBVBHWZYQGJZLR-UHFFFAOYSA-I antimony pentafluoride Chemical compound F[Sb](F)(F)(F)F VBVBHWZYQGJZLR-UHFFFAOYSA-I 0.000 claims abstract description 6
- 150000003797 alkaloid derivatives Chemical class 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 51
- 150000001875 compounds Chemical class 0.000 claims description 46
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 16
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- USVZHTBPMMSRHY-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-chlorophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Cl USVZHTBPMMSRHY-UHFFFAOYSA-N 0.000 claims description 3
- 238000010586 diagram Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000007848 Bronsted acid Substances 0.000 claims description 2
- 239000002841 Lewis acid Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 150000007517 lewis acids Chemical class 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229910018287 SbF 5 Inorganic materials 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract description 10
- ZEOVXNVKXIPWMS-UHFFFAOYSA-N 2,2-dichloropropane Chemical compound CC(C)(Cl)Cl ZEOVXNVKXIPWMS-UHFFFAOYSA-N 0.000 abstract description 8
- 229960000922 vinflunine Drugs 0.000 abstract description 8
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 abstract description 8
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 abstract description 6
- 239000002253 acid Substances 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 abstract description 4
- FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 abstract description 3
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 abstract description 2
- 150000007513 acids Chemical class 0.000 abstract 1
- 150000004820 halides Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 21
- NOSAJPUYIASWEH-ODOBZBQGSA-N methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-4-[(13S,15R,17R)-17-(1,1-difluoroethyl)-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate Chemical compound C([C@@H](C[C@@H](C1)C[C@@]2(C3=C(OC)C=C4N(C)[C@@H]5[C@@]6(C4=C3)CCN3CC=C[C@]([C@@H]63)([C@H]([C@]5(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)C(C)(F)F)N1CCC1=C2NC2=CC=CC=C12 NOSAJPUYIASWEH-ODOBZBQGSA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000005191 phase separation Methods 0.000 description 6
- FFRFGVHNKJYNOV-DOVUUNBWSA-N 3',4'-Anhydrovinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C=C(C2)CC)N2CCC2=C1NC1=CC=CC=C21 FFRFGVHNKJYNOV-DOVUUNBWSA-N 0.000 description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 229960003048 vinblastine Drugs 0.000 description 5
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- -1 silver tetrafluoroborate Chemical compound 0.000 description 4
- 239000011975 tartaric acid Substances 0.000 description 4
- 235000002906 tartaric acid Nutrition 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000004809 Teflon Substances 0.000 description 3
- 229920006362 Teflon® Polymers 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- 229910001494 silver tetrafluoroborate Inorganic materials 0.000 description 3
- 229910000831 Steel Inorganic materials 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 240000001829 Catharanthus roseus Species 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- WVTGEXAIVZDLCR-UHFFFAOYSA-N Vindoline Natural products CC1C2CN3CCCC14CCC5Nc6ccccc6C25C34 WVTGEXAIVZDLCR-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- GKWYINOZGDHWRA-UHFFFAOYSA-N catharanthine Natural products C1C(CC)(O)CC(CC2C(=O)OC)CN1CCC1=C2NC2=CC=CC=C12 GKWYINOZGDHWRA-UHFFFAOYSA-N 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- CXBGOBGJHGGWIE-IYJDUVQVSA-N vindoline Chemical compound CN([C@H]1[C@](O)([C@@H]2OC(C)=O)C(=O)OC)C3=CC(OC)=CC=C3[C@]11CCN3CC=C[C@]2(CC)[C@@H]13 CXBGOBGJHGGWIE-IYJDUVQVSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9704398A FR2761990B1 (fr) | 1997-04-10 | 1997-04-10 | Derives halogenes antimitotiques d'alcaloides de vinca |
| FR97/04398 | 1997-04-10 | ||
| PCT/FR1998/000730 WO1998045301A1 (fr) | 1997-04-10 | 1998-04-10 | Derives halogenes antimitotiques d'alcaloides de vinca |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004059502A Division JP4307292B2 (ja) | 1997-04-10 | 2004-03-03 | ビンカアルカロイドの抗有糸分裂性ハロ誘導体 |
| JP2009058098A Division JP2009167196A (ja) | 1997-04-10 | 2009-03-11 | ビンカアルカロイドの抗有糸分裂性ハロ誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001518892A JP2001518892A (ja) | 2001-10-16 |
| JP2001518892A5 JP2001518892A5 (enExample) | 2004-12-09 |
| JP4401440B2 true JP4401440B2 (ja) | 2010-01-20 |
Family
ID=9505731
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP54247098A Expired - Lifetime JP4401440B2 (ja) | 1997-04-10 | 1998-04-10 | ビンカアルカロイドの抗有糸分裂性ハロ誘導体 |
| JP2004059502A Expired - Lifetime JP4307292B2 (ja) | 1997-04-10 | 2004-03-03 | ビンカアルカロイドの抗有糸分裂性ハロ誘導体 |
| JP2009058098A Pending JP2009167196A (ja) | 1997-04-10 | 2009-03-11 | ビンカアルカロイドの抗有糸分裂性ハロ誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004059502A Expired - Lifetime JP4307292B2 (ja) | 1997-04-10 | 2004-03-03 | ビンカアルカロイドの抗有糸分裂性ハロ誘導体 |
| JP2009058098A Pending JP2009167196A (ja) | 1997-04-10 | 2009-03-11 | ビンカアルカロイドの抗有糸分裂性ハロ誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6127377A (enExample) |
| EP (3) | EP1764368B1 (enExample) |
| JP (3) | JP4401440B2 (enExample) |
| AT (2) | ATE473987T1 (enExample) |
| AU (1) | AU737549C (enExample) |
| BR (2) | BR9816177B1 (enExample) |
| CA (3) | CA2665949C (enExample) |
| CY (2) | CY1111476T1 (enExample) |
| DE (3) | DE69824840T2 (enExample) |
| DK (2) | DK0975640T3 (enExample) |
| ES (2) | ES2222588T3 (enExample) |
| FR (2) | FR2761990B1 (enExample) |
| LU (1) | LU91769I2 (enExample) |
| PT (2) | PT1764368E (enExample) |
| WO (1) | WO1998045301A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009167196A (ja) * | 1997-04-10 | 2009-07-30 | Pierre Fabre Medicament | ビンカアルカロイドの抗有糸分裂性ハロ誘導体 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6890558B2 (en) * | 2002-05-31 | 2005-05-10 | R.P. Scherer Technologies, Inc. | Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment |
| EP1694330A4 (en) * | 2003-12-04 | 2009-06-24 | Amr Technology Inc | DERIVATIVES OF VINORELBINE |
| NZ547370A (en) * | 2003-12-04 | 2010-09-30 | Amr Technology Inc | Vinca derivatives |
| US20110015221A1 (en) * | 2003-12-23 | 2011-01-20 | Pierre Fabre Medicament | Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same |
| FR2863891B1 (fr) * | 2003-12-23 | 2006-03-24 | Pf Medicament | Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation |
| CA2607940C (en) | 2005-05-18 | 2009-12-15 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| FR2894966B1 (fr) * | 2005-12-20 | 2008-03-14 | Pierre Fabre Medicament Sa | Nouvelle forme cristalline de la vinflunine |
| MY159563A (en) | 2006-05-16 | 2017-01-13 | Pharmascience Inc | Iap bir domain binding compounds |
| US20080125451A1 (en) * | 2006-09-12 | 2008-05-29 | Amr Technology, Inc. | Vinorelbine derivatives |
| US8039453B2 (en) * | 2006-09-12 | 2011-10-18 | Albany Molecular Research, Inc. | Vinca derivatives |
| FR2905949B1 (fr) * | 2006-09-20 | 2008-11-21 | Pierre Fabre Medicament Sa | Derives fluores de catharanthine, leur preparation et leur utilisation comme precurseurs d'alcaloides dimeres de vinca |
| FR2910812B1 (fr) | 2006-12-29 | 2009-03-20 | Pierre Fabre Medicament Sa | Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante |
| FR2912406B1 (fr) | 2007-02-13 | 2009-05-08 | Pierre Fabre Medicament Sa | Sels cristalins anhydres de vinflunine, procede de preparation et utilisation en tant que medicament et moyen de purification de la vinflunine. |
| FR2918566B1 (fr) * | 2007-07-11 | 2009-10-09 | Pierre Fabre Medicament Sa | Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine. |
| FR2918567B1 (fr) * | 2007-07-11 | 2012-08-03 | Pf Medicament | Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine. |
| US20090076055A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched vinflunine |
| DE102010020994B4 (de) * | 2010-01-27 | 2022-01-27 | Interpane Entwicklungs-Und Beratungsgesellschaft Mbh | Verfahren zur Herstellung eines beschichteten Gegenstands mit Texturätzen |
| NZ602368A (en) | 2010-02-12 | 2014-10-31 | Pharmascience Inc | Iap bir domain binding compounds |
| US8940754B2 (en) | 2010-02-22 | 2015-01-27 | The Scripps Research Institute | 10′-fluorinated Vinca alkaloids provide enhanced biological activity against MDR cancer cells |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2707988B1 (fr) * | 1993-07-21 | 1995-10-13 | Pf Medicament | Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant. |
| FR2761990B1 (fr) * | 1997-04-10 | 1999-06-25 | Pf Medicament | Derives halogenes antimitotiques d'alcaloides de vinca |
-
1997
- 1997-04-10 FR FR9704398A patent/FR2761990B1/fr not_active Expired - Lifetime
-
1998
- 1998-04-10 EP EP06124480A patent/EP1764368B1/fr not_active Expired - Lifetime
- 1998-04-10 DE DE69824840T patent/DE69824840T2/de not_active Expired - Lifetime
- 1998-04-10 AT AT06124480T patent/ATE473987T1/de active
- 1998-04-10 AU AU73408/98A patent/AU737549C/en not_active Expired
- 1998-04-10 US US09/402,678 patent/US6127377A/en not_active Expired - Lifetime
- 1998-04-10 EP EP20030017052 patent/EP1357125A3/fr not_active Ceased
- 1998-04-10 BR BRPI9816177-6A patent/BR9816177B1/pt not_active IP Right Cessation
- 1998-04-10 JP JP54247098A patent/JP4401440B2/ja not_active Expired - Lifetime
- 1998-04-10 CA CA2665949A patent/CA2665949C/fr not_active Expired - Lifetime
- 1998-04-10 DK DK98920607T patent/DK0975640T3/da active
- 1998-04-10 EP EP98920607A patent/EP0975640B1/fr not_active Expired - Lifetime
- 1998-04-10 DE DE69841766T patent/DE69841766D1/de not_active Expired - Lifetime
- 1998-04-10 ES ES98920607T patent/ES2222588T3/es not_active Expired - Lifetime
- 1998-04-10 PT PT06124480T patent/PT1764368E/pt unknown
- 1998-04-10 CA CA002286560A patent/CA2286560C/fr not_active Expired - Lifetime
- 1998-04-10 ES ES06124480T patent/ES2347878T3/es not_active Expired - Lifetime
- 1998-04-10 AT AT98920607T patent/ATE270297T1/de active
- 1998-04-10 WO PCT/FR1998/000730 patent/WO1998045301A1/fr not_active Ceased
- 1998-04-10 PT PT98920607T patent/PT975640E/pt unknown
- 1998-04-10 DK DK06124480.2T patent/DK1764368T3/da active
- 1998-04-10 CA CA2455416A patent/CA2455416C/fr not_active Expired - Lifetime
- 1998-04-10 DE DE122010000054C patent/DE122010000054I1/de active Pending
- 1998-04-10 BR BRPI9807944-1A patent/BR9807944B1/pt not_active IP Right Cessation
-
2004
- 2004-03-03 JP JP2004059502A patent/JP4307292B2/ja not_active Expired - Lifetime
-
2009
- 2009-03-11 JP JP2009058098A patent/JP2009167196A/ja active Pending
-
2010
- 2010-09-27 FR FR10C0045C patent/FR10C0045I2/fr active Active
- 2010-10-14 CY CY20101100917T patent/CY1111476T1/el unknown
- 2010-12-22 LU LU91769C patent/LU91769I2/fr unknown
- 2010-12-22 CY CY2010019C patent/CY2010019I1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009167196A (ja) * | 1997-04-10 | 2009-07-30 | Pierre Fabre Medicament | ビンカアルカロイドの抗有糸分裂性ハロ誘導体 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4401440B2 (ja) | ビンカアルカロイドの抗有糸分裂性ハロ誘導体 | |
| US5620985A (en) | Antimitotic binary alkaloid derivatives from catharanthus roseus | |
| US4430269A (en) | 12'-Iodo derivatives of dimeric indole-dihydroindole alkaloids, and process for preparing them | |
| MXPA99009264A (en) | Vinca alkaloid antimitotic halogenated derivatives | |
| US4189432A (en) | N-formyl and N-desmethyl leurosine derivatives | |
| HU186282B (en) | Process for the preparation of bisindol compounds | |
| US3242166A (en) | Bis (perfluoroalkyl) diazomethane and preparation thereof | |
| KR850001919B1 (ko) | 20'-하이드록시 빈블라스틴 및 유사화합물의 제조방법 | |
| US3968113A (en) | Conversion of leurosine to vincathicine | |
| Misztal et al. | THE THREO AND ERYTHRO PRODUCTS OF THE CATALYTIC HYDROGENATION OF | |
| EP0033981A2 (en) | Preparation of bridged catharanthus alkaloid dimers | |
| Ozeryanskii et al. | peri-naphthylenediamines: 25. Evidence for the participation of a radical cation of 1, 8-bis (dimethylamino) naphthalene (“proton sponge”) in reactions with nitrating agents. The formation of 1, 1′-binaphthyl “proton sponge” and the regioselective synthesis of 4-chloro-1, 8-bis (dimethylamino) naphthalene | |
| HU181428B (en) | Process for producing leuroformine | |
| US4025522A (en) | Conversion of leurosine to vincathicine | |
| Khokhlov et al. | N-Nitrosation and N-nitration of 3, 3-bis (trifluoromethyl)-containing 2-azabicyclo [2.2. 1] hept-5-enes and heptanes | |
| JP2003503498A (ja) | 置換〔１，４〕ジアゼピノ〔６，７，１−ｈｉ〕インドール−４−オンの製造方法 | |
| Mitsch et al. | Fluorocarbon difluoramines and nitriles | |
| WO2023233129A1 (en) | Macrocyclic compounds comprising tetrafluorophenyl moieties | |
| Rubina et al. | Synthesis of trichloromethyl-substituted azines from dichloromethyl-substituted azines and carbon tetrachloride under interphase catalysis conditions | |
| JPH07110866B2 (ja) | ヴアンクリスチンの製造方法 | |
| Subramanian et al. | Kinetics of the reaction of 2, 4-dinitrochlorobenzene with 4-aminothianes and measurements of the base strengths of the 4-aminothianes | |
| Ozeryanskii et al. | peri-naphthylenediamines | |
| JPS6072866A (ja) | イミダゾ−ル誘導体の製造方法 | |
| JPS6241672B2 (enExample) | ||
| CS214793B2 (en) | New method of making the dimeric disulphides of indol-dihydroindole derivatives genus vinca connected by the bridge |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20040302 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040303 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070904 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071204 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080121 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071228 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080208 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080220 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080324 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081111 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090212 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090323 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090311 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090512 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090807 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090929 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091028 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121106 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121106 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131106 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |